Rami Z. Morsi

TL;DR: The evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in decisions about the use of anticoagulation for thromboprophylaxis for patients with COVID-19-related critical illness and acute illness who do not have confirmed or suspected venous thromboembolism (VTE) as mentioned in this paper.

TL;DR: There are a multitude of interrelated factors at the individual, interpersonal, community and systems levels that drive the implementation, uptake and sustainability of CBHI schemes, particularly in areas where government or employer-based health insurance is minimal.

TL;DR: A systematic review to identify prognostic factors for VTE and bleeding in hospitalized medical patients and searched Medline and EMBASE from inception to May 2018 found moderate certainty evidence shows a probable association with older age, elevated CRP, D-dimer, fibrinogen levels, heart rate and previous history of VTE.

TL;DR: In 2019, the American Society of Hematology (ASH) developed guidelines to support patients, clinicians, and other health care professionals in making decisions about the use of anticoagulation for thromboprophylaxis in patients with COVID-19-related critical illness who do not have confirmed or suspected venous thromboembolism (VTE) as discussed by the authors.

TL;DR: This conditional recommendation was based on very low certainty in the evidence, underscoring the need for additional, high-quality, randomized controlled trials comparing different intensities of anticoagulation in patients with COVID-19-related acute illness.